SCHEMBL14745913

SCHEMBL14745913

COC(=O)c1c(O)c2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1cc3cc(CO[Si](C)(C)C(C)(C)C)n(C)c3cc1C2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 7/20 0.34
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
AADAT Q8N5Z0 1/20 0.33
TSHR P16473 1/20 0.33
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
EDNRB P24530 3/20 0.32
HDAC3 O15379 2/20 0.31
HDAC1 Q13547 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31
HDAC4 P56524 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC9 Q9UKV0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14746202 0.94 EGLN1 (0.35) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL14745717 0.94 EDNRB (0.36) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL14745781 0.93 EGLN1 (0.35) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL16429204 0.93 EGLN1 (0.35) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL14745879 0.88 EGLN1 (0.34) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL14746104 0.88 EGLN1 (0.33) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL14745386 0.88 EGLN1 (0.33) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL14745619 0.87 EGLN1 (0.34) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL16428983 0.87 EGLN1 (0.32) EGLN1ALDH1A1LMNAMAPTAADAT
SCHEMBL16428781 0.85 P2RX3 (0.37) EGLN1ALDH1A1LMNAMAPTAADAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP EGLN1 712/4885ALDH1A1 3792/4885LMNA 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.